Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by Vanguard Personalized Indexing Management LLC

Vanguard Personalized Indexing Management LLC increased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 11.0% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 34,626 shares of the medical research company’s stock after buying an additional 3,445 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Thermo Fisher Scientific were worth $19,148,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Meiji Yasuda Asset Management Co Ltd. grew its position in Thermo Fisher Scientific by 6.5% during the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 20,522 shares of the medical research company’s stock valued at $11,349,000 after purchasing an additional 1,247 shares in the last quarter. Argent Trust Co raised its stake in shares of Thermo Fisher Scientific by 2.5% in the 2nd quarter. Argent Trust Co now owns 22,552 shares of the medical research company’s stock valued at $12,471,000 after buying an additional 551 shares in the last quarter. Meiji Yasuda Life Insurance Co grew its holdings in shares of Thermo Fisher Scientific by 1.2% in the 2nd quarter. Meiji Yasuda Life Insurance Co now owns 15,582 shares of the medical research company’s stock worth $8,617,000 after purchasing an additional 186 shares during the last quarter. Mercer Global Advisors Inc. ADV grew its holdings in shares of Thermo Fisher Scientific by 37.4% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 35,467 shares of the medical research company’s stock worth $19,522,000 after purchasing an additional 9,656 shares during the last quarter. Finally, Lingotto Investment Management LLP bought a new stake in Thermo Fisher Scientific during the 2nd quarter worth about $2,956,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Trading Down 0.6 %

NYSE TMO opened at $610.26 on Wednesday. The firm’s 50 day moving average price is $595.23 and its two-hundred day moving average price is $580.77. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.37 and a current ratio of 1.72. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $627.88. The stock has a market cap of $232.95 billion, a price-to-earnings ratio of 39.14, a PEG ratio of 2.86 and a beta of 0.78.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share for the quarter, topping analysts’ consensus estimates of $5.13 by $0.24. The firm had revenue of $10.54 billion during the quarter, compared to analyst estimates of $10.50 billion. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The business’s revenue was down 1.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $5.15 EPS. Equities analysts anticipate that Thermo Fisher Scientific Inc. will post 21.72 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Friday, September 13th will be paid a dividend of $0.39 per share. The ex-dividend date is Friday, September 13th. This represents a $1.56 annualized dividend and a dividend yield of 0.26%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.01%.

Insider Transactions at Thermo Fisher Scientific

In other news, VP Lisa P. Britt sold 3,624 shares of the company’s stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $613.02, for a total transaction of $2,221,584.48. Following the completion of the sale, the vice president now owns 13,699 shares of the company’s stock, valued at approximately $8,397,760.98. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction on Friday, July 26th. The shares were sold at an average price of $600.85, for a total value of $180,255.00. Following the sale, the executive vice president now directly owns 17,887 shares of the company’s stock, valued at approximately $10,747,403.95. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Lisa P. Britt sold 3,624 shares of the stock in a transaction on Friday, July 26th. The stock was sold at an average price of $613.02, for a total transaction of $2,221,584.48. Following the transaction, the vice president now directly owns 13,699 shares in the company, valued at $8,397,760.98. The disclosure for this sale can be found here. Insiders have sold 23,084 shares of company stock worth $14,094,292 in the last ninety days. Insiders own 0.34% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on TMO. Jefferies Financial Group reissued a “buy” rating and set a $650.00 price target (up from $600.00) on shares of Thermo Fisher Scientific in a research note on Monday, June 3rd. Raymond James upped their price target on shares of Thermo Fisher Scientific from $650.00 to $660.00 and gave the company an “outperform” rating in a report on Thursday, July 25th. Royal Bank of Canada increased their target price on shares of Thermo Fisher Scientific from $660.00 to $664.00 and gave the stock an “outperform” rating in a report on Thursday, July 25th. TD Cowen increased their target price on shares of Thermo Fisher Scientific from $648.00 to $658.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Finally, Robert W. Baird upped their price target on shares of Thermo Fisher Scientific from $620.00 to $632.00 and gave the stock an “outperform” rating in a research report on Thursday, July 25th. Four equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $632.89.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.